NABRIVA THERAPEUTICS PLC's ticker is and the CUSIP is G63637113. A total of 33 filers reported holding NABRIVA THERAPEUTICS PLC in Q2 2021. The put-call ratio across all filers is 0.22 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $16,000 | -80.0% | 90,000 | -52.9% | 0.01% | -74.4% |
| Q1 2022 | $80,000 | -29.8% | 191,028 | 0.0% | 0.04% | +7.5% |
| Q4 2021 | $114,000 | -49.8% | 191,028 | 0.0% | 0.04% | -11.1% |
| Q3 2021 | $227,000 | -12.0% | 191,028 | 0.0% | 0.04% | +9.8% |
| Q2 2021 | $258,000 | -18.6% | 191,028 | 0.0% | 0.04% | -28.1% |
| Q1 2021 | $317,000 | – | 191,028 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ABG Innovation Capital Partners III GP Ltd | 45,849 | $8,000 | 0.60% |
| Aisling Capital Management LP | 90,000 | $16,000 | 0.01% |
| Frazier Life Sciences Management, L.P. | 425,650 | $77,000 | 0.01% |
| Values First Advisors, Inc. | 43,728 | $8,000 | 0.01% |
| Virtu Financial LLC | 127,585 | $23,000 | 0.00% |
| CCG WEALTH MANAGEMENT, LLC | 10,000 | $2,000 | 0.00% |
| Running Point Capital Advisors, LLC | 10,000 | $2,000 | 0.00% |
| WELLS FARGO & COMPANY/MN | 125 | $0 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| GEODE CAPITAL MANAGEMENT, LLC | 42,738 | $7,000 | 0.00% |